title: Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block.
abstract: The signature lesion of autoantibody-associated congenital heart block (CHB) is fibrosis of the conducting tissue. To date, participation of myofibroblasts in the cascade to injury has been unexplored. The importance of myofibroblast/macrophage cross-talk is demonstrated by the novel finding of these cell types in the heart of a neonate dying of CHB. This clue to pathogenesis prompted consideration of the mechanism by which maternal anti-SSA/Ro-SSB/La Abs initiate an inflammatory response and promote fibrosis. Isolated cardiocytes from 16-24 wk abortuses were rendered apoptotic by exposure to poly (2-) hydroxyethylmethacrylate; flow cytometry confirmed surface expression of Ro/La. Apoptotic cardiocytes were incubated with affinity-purified Abs to 52 and 60 kDa Ro from CHB mothers (opsonized) or IgG fractions from healthy donors (nonopsonized). Macrophages cultured with opsonized apoptotic cardiocytes expressed proinflammatory markers, supported by a three-fold increase in active alpha(V)beta(3) integrin. Fetal cardiac fibroblasts exposed to supernatants obtained from macrophages incubated with opsonized apoptotic cardiocytes (but not nonopsonized) dramatically increased expression of the myofibroblast marker alpha-smooth muscle actin (SMAc). The "opsonized" supernatant reversed an inhibitory effect of the "nonopsonized" supernatant on proliferation of fibroblasts (120 vs 69%, p < 0.05). Parallel experiments examined the effects of two cytokines and their neutralizing Abs on fibroblasts. TGFbeta1 increased SMAc staining but decreased proliferation. TNF-alpha did not affect either readout. Addition of anti-TGFbeta1 Abs to the "opsonized" supernatant blocked SMAc expression but increased proliferation, while anti-TNF-alpha blocking Abs had no effects. These data suggest that transdifferentiation of cardiac fibroblasts to a scarring phenotype is a pathologic process initiated by maternal Abs.
authors.affiliation: Department of Rheumatology, Hospital for Joint Diseases, New York University School of Medicine, New York, NY 10003, USA. clancr01@med.nyu.edu
authors.forename: Robert M
authors.initials: RM
authors.lastname: Clancy
authors.forename: Anca D
authors.initials: AD
authors.lastname: Askanase
authors.forename: Raj P
authors.initials: RP
authors.lastname: Kapur
authors.forename: Efstathia
authors.initials: E
authors.lastname: Chiopelas
authors.forename: Natalie
authors.initials: N
authors.lastname: Azar
authors.forename: M Eugenia
authors.initials: ME
authors.lastname: Miranda-Carus
authors.forename: Jill P
authors.initials: JP
authors.lastname: Buyon
mesh_terms: D000974:Antibodies, Antinuclear / Q000378:metabolism; D017209:Apoptosis; D001324:Autoantigens / Q000378:metabolism; D002454:Cell Differentiation; D005260:Female; D005347:Fibroblasts / Q000473:pathology; D005355:Fibrosis; D006327:Heart Block / Q000151:congenital* / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D006329:Heart Conduction System / Q000276:immunology / Q000473:pathology; D006801:Humans; D066298:In Vitro Techniques; D007231:Infant, Newborn; D008262:Macrophage Activation; D008431:Maternal-Fetal Exchange; D009206:Myocardium / Q000473:pathology; D011247:Pregnancy; D020733:RNA, Small Cytoplasmic; D012261:Ribonucleoproteins / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000097585:SS-B Antigen; D000099207:SS-A Antigen
chemical_list: D000974:Antibodies, Antinuclear; D001324:Autoantigens; D020733:RNA, Small Cytoplasmic; D012261:Ribonucleoproteins; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D000097585:SS-B Antigen; D000099207:SS-A Antigen; C116006:RO60 protein, human; C035356:SS-A antibodies; C035357:SS-B antibodies